Nektar therapeutics
NKTR 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分優異，但股利評分未超過2分，若公司開始配息，可能會有更優異的投資結果
NKTR 近期報酬表現
-2.22%
Nektar therapeutics
-0.98%
同產業平均
-0.22%
S&P500
與 NKTR 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
VTGN | Vistagen therapeutics, inc. | 4 分 | 3 分 | 2 分 | 2 分 | 1 分 | |
TNGX | Tango therapeutics inc | 4 分 | 1 分 | 2 分 | 3 分 | 1 分 | |
PSTX | Poseida therapeutics inc | 2 分 | 3 分 | 2 分 | 3 分 | 1 分 | |
DTIL | Precision biosciences inc | 4 分 | 3 分 | 2 分 | 1 分 | 1 分 | |
ANIP | Ani pharmaceuticals inc | 4 分 | 3 分 | 3 分 | 3 分 | 1 分 |
- VTGN Vistagen therapeutics, inc.價值 4 分趨勢 3 分波段 2 分籌碼 2 分股利 1 分查看更多
NKTR 公司資訊
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body's immune response to fight cancer. Its pipeline includes NKTR-255, Rezpegaldesleukin (REZPEG) and NKTR-0165. NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body's innate and adaptive immunity. Its Rezpegaldesleukin pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. Rezpegaldesleukin is being developed as a self-administered injection.